

INCIDENCE OF THROMBOTIC EVENTS IN A COMMERCIALY-INSURED US POPULATION

Susan C. Weller, PhD,^{1,2,3} Laura Porterfield, MD,^{2,3} John W. Davis, BA⁴ Gregg S. Wilkinson, PhD¹, Lu Chen, MS,⁵ Jacques Baillargeon, PhD¹

1. Dept. of Preventive Medicine & Population Health,
2. Dept. of Family Medicine,
3. Sealy Institute for Vaccine Sciences,
4. Population Health Sciences MD/PhD Program,
5. Epidemiology and Biostatistics Consulting Unit, Office of Biostatistics
University of Texas Medical Branch, Galveston, Texas, 77555-1153

Corresponding Author:

Susan C. Weller, PhD

Dept. of Preventive Medicine & Population Health

University of Texas Medical Branch, Galveston, Texas, 77555-1153

Email: sweller@utmb.edu

Funding:

This work was funded in part by a grant from the Texas Academy of Family Physicians Foundation (Weller SC: Does Statin Therapy Reduce VTE Due To Hormone Therapy In Post-Menopausal Women?) and in part by the Sealy Institute for Vaccines Sciences (Weller SC, Porterfield, L: Incidence of Thrombotic Events in a Large, Insured US Population).

Word count: 280 Abstract, 1329 Text

BOX POINTS:

What is already known on this topic?

- Incidence of thrombosis diagnoses vary by country and date.
- There have been improvements in the past decade in thromboprophylaxis (e.g., deep vein thrombosis) and detection (e.g., cerebral venous thrombosis), but there are no recent comprehensive estimates for the United States.

What this study adds:

- Our results document the US incidence of thrombotic and related rare diagnoses for the most recent five-year pre-pandemic period (2015-2019) using a health insurance administrative claims database with approximately 15 million enrollees per year.

ABSTRACT

Objective: To estimate the US incidence of thrombotic events and related rare diagnoses.

Design: Claims-based retrospective cohort study of incidence.

Setting: US commercial health insurance administrative claims database.

Participants: Adults 25-65 years of age between 2015 and 2019 with a minimum of 12 consecutive thrombosis-free months of continuous enrollment beginning 2014 were selected.

Main Outcomes: Age (10 year intervals) and sex stratum specific incidence rates per 100,000 person-years were determined for: venous thromboembolism (VTE), cerebral venous thrombosis (CVT), and any major thrombosis. Incidence also was estimated for immune thrombocytopenic purpura (ITP), hemolytic-uremic syndrome (HUS), and heparin-induced thrombocytopenia (HIT).

Results: Among approximately 15 million enrollees per year (half female/male), incidence of any thrombotic event (DVT, PE, CVT, or other thrombosis) was 247.89 per 100,000 person-years (95% CI: 245.96, 249.84). Incidence of VTE was 213.79 with ICD codes alone (95% CI: 211.99, 215.59) and 127.18 (95% CI: 125.80, 128.58) when also requiring a filled anticoagulation prescription. Incidence rates were 6.37 for CVT (95% CI: 6.07, 6.69), 26.06 for ITP (95% CI: 25.44, 26.78), 0.94 for HUS (95% CI: 0.82, 1.06), and 4.82 for HIT (95% CI: 4.56, 5.10). The co-occurrence of CVT with either ITP or HIT (diagnoses within 14 days of one another) was 0.090 (95% CI: 0.06, 0.13). Incidence tended to increase with age and was higher for women under 55. Incidence for CVT, HUS, and CVT with ITP or HIT was higher for women in all age groups.

Conclusions: These results are the first US estimates for incidence of thrombotic and rare events in a large, commercially-insured US population. Findings provide a critically important reference for determining excess morbidity associated with COVID-19 and more generally for vaccine pharmacovigilance.

Although interest in incidence of rare thrombotic events (e.g., cerebral venous thrombosis, CVT) has increased with recent COVID-19 disease and vaccine adverse event surveillance,¹⁻³ few recent estimates exist for the United States. This study estimates the pre-pandemic incidence of thrombotic events and rare conditions associated with thrombocytopenia that are potentially associated with COVID-19 disease and/or vaccination. Using a large, US commercial healthcare administrative database, we provide the first estimates of incidence, since improvements over the past decade in prevention and detection of thromboses. These data will be useful in evaluating morbidity associated with COVID-19 disease and more generally, for pharmacovigilance.

Incidence estimates for thrombotic events have been inconsistent and limited by population size. The focus has been on the more common diagnosis of venous thromboembolism (VTE), lower extremity deep vein thrombosis (DVT) and/or pulmonary embolism (PE), but estimates are highly variable across populations.⁴⁻⁶ Limited data are available on the incidence of rarer thromboses because samples were too small to detect events. Recently, a report from Denmark⁵ estimated combined incidence for major venous thromboses, as well as for VTE alone, and data from the European Union (EU) and the United Kingdom (UK)⁶ estimated CVT incidence.

In this study, incidence of VTE, CVT, other thromboses, immune thrombocytopenic purpura (ITP), hemolytic-uremic syndrome (HUS), and heparin-induced thrombocytopenia (HIT) was estimated using administrative data from a large, US commercial health insurance program. Incidence was estimated stratified by sex and age, among adults aged 26-65 for the most recent five-year period prior to the pandemic (2015-2019).

Methods

Diagnoses were identified in Optum's de-identified Clinformatics® Data Mart Database, containing inpatient and outpatient claims for approximately 62 million unique enrollees.⁷ Excluding Medicare Advantage subscribers, there are approximately 15 million annual members, a third of whom have continuous enrollment for three or more years.

Diagnoses were identified for: acute VTE (DVT: ICD-9: 451.1x, 451.2x, 451.81, 451.83; ICD-10: I80.1x, I80.2x, I80.3, I80.219; PE: ICD-9: 415.1x, ICD-10: I26.0x, I26.9x); CVT (ICD-9: 325.0, 437.6; ICD-10: G08, I67.6, I63.6) and other major thromboses (portal vein thrombosis, hepatic vein thrombosis/Budd-Chiari syndrome, thrombophlebitis migrans, embolism or thrombosis of vena cava (inferior), embolism or thrombosis of renal vein, or mesenteric thrombosis: ICD-9: 452, 453.0, 453.1, 453.2, 453.3, 557.0; ICD-10: I81, I82.0, I82.1, I82.2, I82.3, K55.0H). Additional diagnoses were ITP (ICD-9: 287.31; ICD-10: D69.3), HUS (ICD-9: 283.11; ICD-10: D59.3), and HIT (ICD-9-CM 289.84; ICD-10: D75.82). VTE incidence was first estimated using ICD codes alone and second requiring that an anticoagulant be filled within 30 days (excluding “flush” formulations of heparins) or disenrollment within 30 days.

Incidence was calculated as the frequency of each diagnosis divided by disease-free person-time across a five-year period. All enrollees between 26 and 65 years of age with a minimum of 12 consecutive months enrollment were followed from January 1, 2014 to December 31, 2019. Rates were calculated by sex and ten-year age categories: 26-35, 36-45, 46-55, and 56-65. A 12 month event-free lookback period was required for each outcome, before follow-up began. Denominators contained time each enrollee contributed during follow-up, censored at time of diagnosis, turning 65, or disenrollment. Because Medicare begins at age 65, we limited follow-up to enrollees under 65.

Results

For enrollees 25-65 years of age, incidence of any thrombotic event (VTE, CVT, or other major thrombosis) was 247.89 per 100,000 person-years (95% CI: 245.96, 249.84; 62,598 cases with 25,252,020 person-years). Rates increased with age and were higher for women than for men until age 55, with larger sex differences at younger ages (for all outcomes, see Table for rates per 100,000 for subgroups and overall; see online Appendix for number of cases, person-years, and incidence).

Incidence of VTE was 213.79 per 100,000 person-years (95% CI: 211.99, 215.59). Incidence of VTE, DVT without PE (47.73; 95% CI: 46.88, 48.58), and PE with or without DVT (171.18;

95% CI: 169.58, 172.80) had similar sex by age patterns with higher rates at older ages and higher rates for women younger than 55 (Appendix). With a more restrictive estimate of VTE (requiring anticoagulation), the incidence of VTE (VTE+a, Table) was 127.18 (95% CI: 125.80, 128.58); 16.32 for DVT alone (95% CI: 15.88, 16.82) and 113.35 for PE with or without DVT (95% CI: 112.05, 114.67). With the restricted definition, rates were higher for women younger than 46.

Incidence per 100,000 person-years was 6.37 for CVT (95% CI: 6.07, 6.69). Incidence for ITP was 26.06 (95% CI: 25.44, 26.78), 4.82 for HIT (95% CI: 4.56, 5.10), and 0.94 for HUS (95% CI: 0.84, 1.06). Incidence was higher in women for all ages for CVT and HUS. Rates for the co-occurrence of CVT with other diagnoses (within 14 days) was 0.04 with ITP (95% CI: 0.02, 0.06), 0.06 with HIT (95% CI: 0.03, 0.09), and 0.09 with either ITP or HIT (95% CI: 0.06, 0.13). For the co-occurrence of CVT with other events (Appendix), incidence was higher for women under 55, but was higher for women of all ages for CVT with ITP or HIT.

Discussion

This is the first report to provide comprehensive age and sex-stratified incidence estimates for thrombotic and other rare events in the United States, although the cohort is limited to insured enrollees and does not include those uninsured or with other insurance carriers. Estimates cover the most recent period before the COVID-19 pandemic. Rates increased with older age for most outcomes and tended to be higher for women under 55. Incidence for CVT, HUS, and CVT with ITP or HIT was higher for women at all ages.

Incidence for VTE ranged from 127 per 100,000 person-years when an anticoagulant was required to 214 when using only ICD codes. The higher estimate includes cases, as well as suspected cases, and likely overestimates the true rate. It is, however, the method used in other studies.⁵ The lower estimate may underestimate the true incidence as anyone receiving – but not filling – their anticoagulant prescription would be excluded, which may occur as often as in 40% of cases.⁸ Thus, results may be limited by use of administrative-level data and not detailed

medical records. However, these estimates may provide upper and lower bounds on true VTE incidence in the United States.

Population differences in rates are notable, as confidence intervals between studies often do not overlap. In the past decade, VTE incidence per 100,000 person-years ranged from 150 in the UK⁶ to 200 in Spain⁶ for adults of all ages (Figure 1 for recent estimates; more comprehensive review of studies in Appendix).⁴⁻⁶ A recent report from Denmark⁵ estimated incidence (2010-2018) for VTE alone at 170 and 176 for a broader category of venous thromboses among those 18-99 years of age in a population base of five million. For those 18-64 years of age, incidence was 95 for any venous thrombosis and 91 for VTE. Here, rates for similar age and time ranges were twice as high (248 for any venous thrombosis, 214 for VTE).

CVT estimates may appear more consistent across populations, but also may have non-overlapping confidence intervals (Appendix). In the past decade, CVT rates per 100,000 ranged from 0.12 in the UK⁶ to 2.00 in New York/Florida in the US⁹ (Figure 2 for recent estimates,^{6,9,10} more comprehensive review in Appendix). In this analysis, CVT incidence (6.37) was several times higher than reported in European countries and three times higher than New York/Florida. In contrast, the ITP rate in this study (26.06) fell within the range of 2019 European rates from 20.12 in the UK to 95.71 in Spain.⁶ Inconsistencies across studies may be due to differences in underlying population characteristics (age, smoking, obesity, and comorbidities), lack of standardization, differences in included ICD codes, or detection bias.

This is the first comprehensive US report on incidence of these conditions, since advances have been made in the past decade in thromboprophylaxis and detection. Furthermore, this report contains some of the first population-based rates for the incidence of rare events associated with thrombocytopenia. Rates will be useful when determining excess morbidity linked to COVID-19 and more generally for vaccine adverse event surveillance.^{11,12}

REFERENCES

1. Pinho AC. AstraZeneca's COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low platelets. European Medicines Agency. Published April 6, 2021. Accessed April 12, 2021. <https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood>
2. Steenhuisen PA Julie. J&J COVID-19 vaccine under EU review over blood clots. *Reuters*. <https://www.reuters.com/article/us-health-coronavirus-europe-vaccines-idUSKBN2BW2FI>. Published April 9, 2021. Accessed April 12, 2021.
3. See I, Su JR, Lale A, et al. US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COVS.2 Vaccination, March 2 to April 21, 2021. *JAMA*. Published online April 30, 2021. doi:10.1001/jama.2021.7517
4. Delluc A, Tromeur C, Ven FL, et al. Current incidence of venous thromboembolism and comparison with 1998: a community-based study in Western France. *Thromb Haemost*. 2016;116(11):967-974. doi:10.1160/TH16-03-0205
5. Østergaard SD, Schmidt M, Horváth-Puhó E, Thomsen RW, Sørensen HT. Thromboembolism and the Oxford–AstraZeneca COVID-19 vaccine: side-effect or coincidence? *The Lancet*. 2021;0(0). doi:10.1016/S0140-6736(21)00762-5
6. Williame C, Dodd C, Gini R, Duran C. Background rates of Adverse Events of Special Interest for monitoring COVID-19 vaccines, an ACCESS study. Published online April 30, 2021. Accessed May 6, 2021. http://www.encepp.eu/documents/ACCESS_Report_BGR_20210430_v.1.2.pdf
7. Optum De-Identified Market Clarity Data (2007-2020). <https://www.optum.com/business/solutions/life-sciences/explore-data/advanced-analytics/market-clarity-data.html>
8. Burton T, Hlavacek P, Guo JD, et al. Clinical characteristics and treatment patterns of patients with venous thromboembolism (VTE) transitioning from hospital to post-discharge settings. *Hosp Pract*. 2020;48(4):196-205. doi:10.1080/21548331.2020.1769988
9. Otite FO, Patel S, Sharma R, et al. Trends in incidence and epidemiologic characteristics of cerebral venous thrombosis in the United States. *Neurology*. 2020;95(16):e2200-e2213. doi:10.1212/WNL.0000000000010598
10. Devasagayam Sharon, Wyatt Ben, Leyden James, Kleinig Timothy. Cerebral Venous Sinus Thrombosis Incidence Is Higher Than Previously Thought. *Stroke*. 2016;47(9):2180-2182. doi:10.1161/STROKEAHA.116.013617
11. Pottegård A, Lund LC, Karlstad Ø, et al. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford–AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study. *BMJ*. 2021;373:n1114. doi:10.1136/bmj.n1114

12. Yih WK, Greene SK, Zichittella L, et al. Evaluation of the risk of venous thromboembolism after quadrivalent human papillomavirus vaccination among US females. *Vaccine*. 2016;34(1):172-178. doi:10.1016/j.vaccine.2015.09.087

TABLE: INCIDENCE BY AGE AND SEX PER 100,000 PERSON-YEARS					
Sex	Age				Total
	26-35	36-45	46-55	56-65	
<u>VTE (DVT OR PE)</u>					
Female	95.26	161.16	235.13	374.65	224.14
Male	51.31	105.99	221.53	416.33	203.74
Total	72.43	132.87	228.27	395.31	213.79
<u>VTE+a (DVT+a OR PE+a)</u>					
Female	51.12	89.14	127.95	209.51	123.76
Male	29.37	65.00	141.80	272.13	130.50
Total	39.83	76.76	134.93	240.53	127.18
<u>CVT</u>					
Female	8.61	8.93	8.07	8.25	8.45
Male	2.54	2.70	4.52	7.39	4.36
Total	5.46	5.74	6.28	7.82	6.37
<u>ANY THROMBOSIS (DVT, CVT, and other)*</u>					
Female	113.72	187.86	272.82	426.94	258.85
Male	61.13	123.55	255.92	485.99	237.27
Total	86.40	154.87	264.29	456.20	247.89
<u>ITP</u>					
Female	30.38	27.09	27.80	38.23	30.99
Male	9.73	13.06	20.77	39.97	21.29
Total	19.66	19.90	24.25	39.09	26.06
<u>HUS</u>					
Female	0.96	1.08	1.38	1.51	1.25
Male	0.38	0.56	0.75	0.78	0.63
Total	0.66	0.81	1.07	1.15	0.94
<u>HIT</u>					
Female	1.52	1.92	4.01	9.41	4.41
Male	0.58	1.99	5.24	12.43	5.22
Total	1.03	1.96	4.63	10.90	4.82

* Any thrombosis: VTE, CVT, portal vein thrombosis, hepatic vein thrombosis/Budd-Chiari syndrome, thrombophlebitis migrans, embolism or thrombosis of vena cava (inferior), embolism or thrombosis of renal vein, or mesenteric thrombosis.